Clinical trial
Growth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00163215 |
|---|---|
| Title | Growth Retardation In Children With Special Pathological Conditions Or Disease |
| Official title | Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Endocrine System Diseases |
| Intervention type | Drug |
| Interventions | Somatropin |
| Enrollment | 46 |
| Start date | Jan 1, 2005 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Sep 13, 2005 |
| Last update posted | Dec 19, 2012 |
| Countries | France |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: